AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC.

Discover how digital innovation in clinical trial technology—eClinical platforms, remote data capture, and decentralized ...

A team of researchers from Keio University School of Medicine, Kyoto Prefectural University of Medicine, and Teikyo ...

Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based ...

AI guidance for clinicians aimed at reducing the spread of Clostridioides difficile—a bacteria that can be deadly for sick ...

In order for doctors to trust AI in a clinical setting, artificial intelligence must explain its clinical decisions and cite sources, according to an association report.

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

Chemotherapy is a vital treatment for people with all forms of cancer. It's a process that uses drugs designed to kill, ...

Mohammed Sadhik Shaik, a researcher and IT specialist, is addressing this issue through ongoing work on Blockchain and ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Recent studies assessed artificial intelligence (AI) assistance tools in their ability to provide quality medical recommendations for patients.

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.